The Oncology Institute

The Oncology Institute, Inc. provides cancer care treatment services. It offers evidence-based cancer care to patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. The company is headquartered in Cerritos, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The Oncology Institute reports strong revenue growth amidst operational challenges

TOI's Q1 2024 performance showcased robust revenue growth driven by strategic partnerships and record prescription sales, despite challenges with drug margin compression.
Operational achievements and a healthy cash position provide a strong foundation for TOI to navigate challenges and capitalize on growth opportunities in the oncology market.
By focusing on strategic priorities outlined by CEO Daniel Virnich, TOI aims to enhance profitability, expand market presence, and lead in value-based oncology care.

The Oncology Institute reports strong Q2 growth amid margin challenges

TOI's Q2 2024 earnings call reflected strong revenue growth but challenges with margins and profitability. The company is focused on addressing margin pressures and enhancing shareholder value through strategic initiatives.

The Oncology Institute reports robust Q3 growth and strategic focus

TOI's Q3 2024 performance reflects strong revenue growth, cost management, and strategic initiatives to drive operational efficiency and compliance.
The company's strengths lie in proactive cost optimization, expanded service offerings, and a clear strategic direction towards growth and performance.
Challenges include regulatory compliance, profitability sustainability, and ongoing efforts to balance financial flexibility with quality care delivery.
Opportunities abound in stable revenue streams, strategic partnerships, and enhanced profitability through optimized cost structures and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Oncology Institute, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.

The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2022 Earnings Conference Call May 11, 2022 5:00 PM ET Company Participants Mihir Shah – Chief Financial Officer Brad Hively – Chief Executive Officer Conference Call Participants Brian Tanquilut – Jefferies Gary Taylor – Cowen Operator Good afternoon and welcome to The Oncology Institute's First Quarter 2022 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepare marks and Q&A.

The Oncology Institute, Inc's (TOI) CEO Brad Hively on Q1 2022 Results - Earnings Call Transcript

CERRITOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its first quarter ended March 31, 2022.

The Oncology Institute Reports First Quarter 2022 Financial Results and Confirms Full Year 2022 Guidance

Savings equated to nearly $4,000 per patient episode in most recent OCM performance period Savings equated to nearly $4,000 per patient episode in most recent OCM performance period

The Oncology Institute Reaches $9.5M Total Saved to Medicare While Exceeding Quality Benchmarks

Shah Brings 15 Years of Financial Leadership in Public and Private Healthcare Companies Shah Brings 15 Years of Financial Leadership in Public and Private Healthcare Companies

The Oncology Institute Names Mihir Shah as Chief Financial Officer

TOI continues investment into Southern California clinical presence TOI continues investment into Southern California clinical presence

The Oncology Institute Adds New Culver City Clinic and Expands Riverside Location

The Oncology Institute, Inc. (TOI) CEO Brad Hively on Q4 2021 Results - Earnings Call Transcript

CERRITOS, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and full year ended December 31, 2021 and provided an update on its business including guidance for the year ending December 31, 2022.

The Oncology Institute Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Strong Growth Outlook for 2022

CERRITOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, will participate at the Jefferies Value-Based Healthcare Summit in Miami, Florida, on Monday, March 14. Hively will host a fireside chat at the conference at 1:40 pm EST.

The Oncology Institute to Participate at the Jefferies Value-Based Healthcare Summit

Leaders Will Take on Expanded Roles in Response to TOI's Rapid Growth Leaders Will Take on Expanded Roles in Response to TOI's Rapid Growth

The Oncology Institute Announces Promotions for Dr. Daniel Virnich and Dr. Matt Miller

TOI Will Serve Pinellas and Hillsborough County, With Additional Markets Planned TOI Will Serve Pinellas and Hillsborough County, With Additional Markets Planned

UPDATE - The Oncology Institute Enters Into Value-Based Agreement with MaxHealth

The Oncology Institute Enters Into Value-Based Agreement with MaxHeath

Expansion into Polk County Adds the 54th Clinic Location for the Practice Expansion into Polk County Adds the 54th Clinic Location for the Practice

The Oncology Institute Expands Florida Presence with Lakeland Clinic, Physician Dispensary

The Oncology Institute manages community-based oncology practices numbering 55 across four states in the U.S.

The Oncology Institute: Capitalizing On Clinical Research Contracts

DFP Healthcare Acquisitions Corp

NEW YORK and LOS ANGELES, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The Oncology Institute (“TOI” or “The Company”), the U.S. market leader in value-based oncology care, announced today that it has closed its previously announced business combination with DFP Healthcare Acquisitions Corp. (“DFPH”). The transaction was approved at a special meeting of DFP's stockholders on November 12, 2021.

UPDATE - The Oncology Institute Completes Business Combination with DFP Healthcare Acquisitions Corp. to Become Publicly-Traded Company

Addition of Yang Practice Marks Fourth Acquisition in Q4 Addition of Yang Practice Marks Fourth Acquisition in Q4

The Oncology Institute Adds San Gabriel Valley Practices to Network

News for The Oncology Institute Stock (TOI)